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Abstract 
Background: Hyperpigmentation is a skin disorder characterized by elevated production of melanin. Current 
treatment approaches mainly rely on the application of skin lightening chemicals, most of which have safety issues. 
Efficacy of delivery of the active ingredients to the target organ has also been a challenge. Transdermal based 
drug delivery platform has been shown to improve drug bioavailability, avoiding the hepatic first pass metabolism, 
decrease gastrointestinal side effects, and eventually enhance patient compliance.
Results: This article explores the utilization of micellar transdermal delivery technology to improve skin penetration 
and efficacy of arbutin, a hyperpigmentation agent. The suppression efficacy of cellular melanin production versus 
cell viability of four active ingredients commonly used in skin lightening products, namely allantoin, arbutin, gly-
colic acid, and hyaluronic acid were first compared. Arbutin was selected for the micellar delivery studies base on its 
comparatively low cytotoxicity and better performance in reducing melanin production. Micellar Arbutin cream was 
formulated using Urah® proprietary micellar technology and was assessed for its cellular melanin suppression efficacy 
and skin penetration capacity.
Conclusion: The results show that micellar arbutin cream improved both the delivery and cellular melanin suppres-
sion, suggesting that micellar transdermal delivery may have potential application in addressing hyperpigmentation 
skin disorders.
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Background
Melanin is an irregular light absorbing polymer produced 
by the melanocytes which are located in the basal layer of 
epidermis [1]. Melanin protects human skin and under-
lying tissues against ultraviolet (UV) rays and absorption 
of toxic chemicals [2]. However, excessive formation or 
accumulation of melanin in the skin causes hyperpig-
mentation skin disorders [3]. Melanin formation in skin 
cells can be reduced or blocked by some chemicals which 
are the common active ingredients in skin lightening 
products [4, 5]. Most of the chemicals decrease the pro-
duction of melanin by suppressing tyrosinase, an enzyme 
governing melanin production. So that as existing skin 
cells are naturally exfoliated keratinocytes with less mela-
nin come to the surface and provide a lighter skin [6, 7].
To reach the skin cells, however, the chemicals have 
to pass through the stratum corneum, which acts as 
highly resistant lipid barrier to penetration of foreign 
molecules into the skin [8]. Therefore in both the phar-
maceutical and cosmetic fields, significant efforts have 
been put forth in attempts to overcome the barrier of the 
stratum corneum in order to deliver topically functional 
agents into the skin. For example, Kim disrupted the stra-
tum corneum by using dissolving microneedle patch to 
deliver 4-n-butylresorcinol, a skin depigmentation agent 
[9]. Cell penetrating peptide conjugated liposomes were 
also used to enhance transdermal delivery of Polygonum 
aviculare L. extract [10]. Recently, lecithin organogel 
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was described as a unique micellar system for the topical 
delivery of drugs and bioactive agents including tacroli-
mus, vitamins A and C, kojic acid, glycolic acid and other 
molecules [11, 12]. To the best of our knowledge there is 
no record of application of micelles for the transdermal 
delivery of arbutin.
In this article, we compare the suppression efficiency 
of cellular melanin production by four active ingredi-
ents commonly used in skin lightening products, namely 
allantoin, arbutin, glycolic acid, and hyaluronic acid. 
Due to comparatively lower cytotoxicity and higher 
performance in reducing melanin production, arbutin 
was selected from the four candidates for further stud-
ies. 5  % (w/w) arbutin was encapsulated in a micellar 
matrix of the cream with the view to ascertain possible 
effect of micellar formulation. Both the micellar and the 
non-micellar arbutin (containing 5 % w/w arbutin) were 
screened for their ability to suppress melanin production 
in a B16-F10 mouse melanoma cell line. Furthermore, 
we performed ex  vivo skin penetration experiments in 
a Franz cell using fresh porcine skin to demonstrate the 
transdermal permeability of the micellar arbutin.
Methods
Glycolic acid (≥97  %) and allantoin (≥98  %) were pur-
chased from Fluka. Melanin, arbutin (≥98  %), hyalu-
ronic acid (≥98  %), and Penicillin–Streptomycin were 
purchased from Sigma-Aldrich. phosphate buffer saline 
(PBS) with pH 7.4 (1×), fetal bovine serum (FBS), and 
Dulbecco minimum essential medium (DMEM) were 
purchased from Gibco. Alamar blue was purchased from 
Invitrogen. The porcine skin was obtained from the local 
supermarket and doesn’t require any ethical approval 
according to the national regulations. The care and use of 
laboratory animals used in preliminary study were moni-
tored according to the approved protocols (BRC IACUC 
#151001) of the Institutional Animal Care and Use Com-
mittee (IACUC) at the Biological Resource Center (BRC) 
in Biopolis, Singapore.
Cell culture
B16-F10 mouse melanoma cell line (ATCC) was main-
tained in DMEM containing 10 % FBS and 1 % Penicil-
lin–Streptomycin (full medium) at 37 °C under 5 % CO2.
Suppression of cellular melanin production
Four different agents (arbutin, glycolic acid, hyaluronic 
acid, and allantoin) were screened for their ability to 
suppress the melanin production through cell experi-
ment. Briefly, B16-F10 cells were seeded at a density of 
8000 cells per well in a 96 well plate 24 h before experi-
ments. The original culture medium in the wells was then 
replaced with medium containing various concentrations 
(0.1  mg/ml, 1  mg/mg, and 5  mg/ml) of the above four 
agents. The concentrations were selected based on the 
concentration ranges usually found in commercial prod-
ucts (allantoin (recommended dosage is 0.5–2  %) [13, 
14], arbutin (concentrations reported in the literature is 
3–7 %) [15], glycolic acid (concentration reported in liter-
ature is 4–70 %) [16–18], and hyaluronic acid (concentra-
tion is up to 1 %) [19]). The serum concentration (10 %) 
was controlled to be the same for all wells. The culture 
was maintained for 5  days, during which each well was 
imaged every day. On day five, the media from all wells 
was transferred to a new plate and quantified for the 
absorbance at 405  nm on UV–Visible spectrophotom-
eter (Shimadzu, UV-2450). The concentration of melanin 
at each well was estimated by correlating the measured 
absorbance with the standard curve between the melanin 
concentration and absorbance.
Cell viability assay
Alamar blue assay was carried to analyze the cell viability 
after the incubation with various concentrations of arbu-
tin, glycolic acid, hyaluronic acid, and allantoin. Briefly, 
8000 cells were seeded per well in a 96 well plate  24  h 
before the experiment. Then various concentrations 
of arbutin, glycolic acid, hyaluronic acid, and allantoin 
(0.1  mg/ml, 1  mg/mg, and 5  mg/ml) were added to the 
wells for 24  h. Later, 10  µl of Alamar blue was directly 
added to the wells for 2  h. The absorbance at 600  nm 
was measured (Spectramax M5 Microplate/Cuvette 
Reader System, Molecular Devices). A series of cell dilu-
tions were prepared to derive a standard curve between 
absorption and cell concentration.
Micellar arbutin
Typically, when the cream containing functional ingre-
dients is applied on the skin, the emulsion stability may 
be affected by the changes in the relative concentration 
of the continuous phase (solvent) on the skin environ-
ment. This presents a formulation challenge for effective 
transdermal products. Both the emulsion stability and 
the efficacy of absorption of the active ingredients may 
be affected by the changes in the continuous phase. The 
Urah® micellar system used here incorporates reverse 
micellar transformation capability to address the change 
in the concentration of the continuous phase on the skin, 
thus enabling the micelle to work both as a solubilizer 
and delivery vehicle on the skin [20]. The production of 
arbutin-encapsulated micelles or micellar arbutin cream, 
was done by using the proprietary formulation method 
from Urah® Transdermal Pte Ltd (Singapore) which 
comprises of the encapsulation of 5 % arbutin in a stable 
emulsion matrix using Urah® patented bio-surfactants 
[20]. The non-micellar arbutin cream (cream containing 
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5  % arbutin without encapsulated micelles) was for-
mulated using the standard oil-in-water emulsification 
approach [21].
Suppression of cellular melanin production with micellar 
arbutin cream
This experiment was performed using the 24-well plate 
for transwell migration assay (8  µm pore, Cell Biolabs 
Inc.). 24 h before experiment, B16-F10 cells were seeded 
to the bottom chamber at a density of 8 × 104 cells/well 
in 0.5  ml full medium. Then 100  mg of micellar arbu-
tin cream, 100  mg of non-micellar arbutin cream (see 
the section above), or 5  mg of free arbutin powder was 
added onto the upper well. The plate was incubated at 
37 °C with 5 % CO2 for 5 days. Every day, the cells were 
imaged. 5 days later, the upper wells were removed and 
the absorbance of the media at the bottom chamber at 
405 nm was measured with Spectramax M5 Microplate/
Cuvette Reader System (Molecular Devices). The blank 
cream containing no arbutin was used as a control.
Ex vivo skin penetration study with Franz cell
Fresh porcine skin (abdominal skin) was used in the 
ex vivo skin permeation studies. The hair and subcutane-
ous fat were carefully removed before experiment. The 
porcine skin was placed and clamped between the donor 
and receptor compartments of a Franz cell assembly with 
the stratum corneum of the skin piece facing the donor 
compartment. The receiving compartment was filled 
with PBS, avoiding the air bubbles between the underside 
of the skin and the PBS solution. 1 g of micellar arbutin 
cream, 1  g of non-micellar arbutin cream or the blank 
cream (no arbutin) was applied homogeneously onto the 
stratum corneum of the skin. A magnetic stirrer was put 
into the bottom of Franz cell, which stirred continuously 
at 400 rpm. The PBS solution was sampled (100 µl) at 1, 
2, 4, 8, 12 and 24 h respectively. Same volume of PBS was 
refilled back to the Franz cell each time after sampling.
The transmigrated arbutin was quantified by high per-
formance liquid chromatography (HPLC) (Agilent 1100 
HPLC VWD) on a LC column (Poroshell, 120 EC-C18, 
4.6  ×  100  mm, 2.7  µm) and detected at 222  nm. The 
mobile phase was a mixture of water:methanol:0.1  M 
hydrochloric acid (89:10:1, v/v/v) with 0.5  ml/min flow 
rate. The area of the arbutin peak was measured and con-
verted to the concentration based on the standard curve.
Statistical analysis
All statistics were performed with the Origin Pro 
8.0 (OriginLab). The data were analyzed by one-way 
ANOVA. *P < 0.05, **P < 0.01 were considered to indicate 
a statistically significant difference.
Results and discussion
Melanin suppression activity and cytotoxicity
Allantoin, arbutin, glycolic acid, and hyaluronic acid were 
firstly compared for their suppression of melanin produc-
tion in B16-F10 mouse melanoma cells. The cells were 
incubated with these chemicals under four concentra-
tions (0, 0.1, 1 and 5 mg/ml) for 5 days. At day 5, the cell 
medium was transferred to a new plate and the secreted 
melanin concentrations for each well were quantified 
by measuring the absorption at 405  nm and correlating 
the results to the concentration-UV absorption standard 
curve (Additional file 1: Figure S1). The viability of cells 
left in the original plate were analysed using alamar blue 
assay.
Based on the quantification of secreted melanin 
(Fig. 1a), glycolic acid had the strongest effect in inhibit-
ing the melanin production at the 1 and 5 mg/ml concen-
trations whereas allantoin was the least effective at both 
1 and 5 mg/ml. However, the cell quantification (Fig. 1b) 
revealed that both glycolic acid and hyaluronic acid were 
cytotoxic. The remaining numbers of cells in the wells 
after treatment with 1 and 5 mg/ml glycolic acid repre-
sented only 20–30 % of numbers of cells detected in the 
control wells. The daily imaging suggested that the lower 
melanin amounts observed for glycolic and hyaluronic 
acids were due to the decrease of cell viability (Additional 
file 1: Figure S2). In comparison, both allantoin and arbu-
tin did not show any influence over the cell viability and 
proliferation at the three concentrations used.
Given the higher cell viability and relatively effective 
inhibition of cellular melanin production, arbutin was 
chosen for further micellar formulation studies.
Micellar arbutin is a formulation with active arbutin
The cream with micelle encapsulated arbutin (or micel-
lar arbutin cream) with 5 % arbutin (w/w) was prepared 
as described in the experimental section. This was com-
pared with the non-micellar arbutin cream. Through 
dynamic light scattering study (Additional file  1: Figure 
S3), the micellar arbutin was around 90  nm, which was 
close to the size of blank micelle (70 nm). If the arbutin 
was not encapsulated within the micelles, the particle 
size was around 250 nm.
To test whether the micellar arbutin retains its origi-
nal melanin-suppression ability, we co-cultured the B16-
F10 cells with non-micellar arbutin cream, free arbutin, 
micellar arbutin cream, and blank cream in a transwell 
(Fig.  2a). Transwell was used to prevent the physical 
contact between cream and cells. We expected that the 
melanin suppression efficiency of micellar arbutin cream 
would be somewhat lower in comparison to free arbutin, 
since the micelles with arbutin had to leave the cream 
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phase before they got into the medium with cells. Based 
on the comparative melanin concentrations, addition of 
free arbutin reduced melanin concentration by 40 % (rel-
atively to the blank cream), micellar arbutin reduced mel-
anin concentration by about 25 %, whereas non-micellar 
arbutin by 10 % (Fig. 2b). In addition, we did not see any 
significant cytotoxicity of micellar arbutin in the 5-days 
long experiment. Cells in the wells with free arbutin, 
micellar arbutin, non-micellar arbutin, and blank cream 
grew and proliferated at similar rates (Additional file  1: 
Figure S3). Thus, the micellar arbutin cream has strong 
advantage in the suppression of melanin production 
while retaining its safety credentials.
Micellar arbutin cream shows enhanced transdermal 
activity
We examined the skin penetration capacity of micellar 
arbutin in a static Franz diffusion cell (Fig. 3a). Fresh pig 
skin after the removal of fat and hair was used due to its 
similarity to human skin [22]. The transmigrated arbutin 
in the receiving well was quantified by HPLC (Additional 
file 1: Figure S4). The area of arbutin peak, identified with 
Fig. 1 Comparison of allantoin, arbutin, glycolic acid, and hyaluronic acid: a suppression of melanin production at 0.1, 1, and 5 mg/ml in a 5-day 
culturing. b Cell quantification after a 5-day culturing. *P < 0.05, **P < 0.01, as determined by one-way ANOVA
Fig. 2 Micellar arbutin cream for the suppression of cellular melanin production: a illustration of the transwell experiment. b Melanin quantification 
after a 5-day culturing. Results represent the mean ± standard deviation of three independent cultures and determinations. *P < 0.05 compared 
with the sample treated with blank cream, as determined by one-way ANOVA
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standard samples was quantified and converted to the 
arbutin concentration by correlating with the standard 
curve (Additional file 1: Figure S5). As shown in Fig. 3b, 
there was a slight increase in the concentration of arbutin 
in the receiving well after 1  h for both micellar arbutin 
cream and non-micellar arbutin cream, in comparison 
to the blank cream. This suggests that same level of pas-
sive diffusion was taking place in both non-micellar arbu-
tin at the initial stage. Four hours upon application, the 
micellar arbutin cream showed gradual increase in the 
concentration of arbutin delivered through the skin in 
comparison with non-micellar arbutin cream. The differ-
ence nearly doubled after 12  h. These data suggest that 
micellar arbutin cream can improve the steady delivery of 
arbutin through the skin over a long period of time.
Conclusion
Hyperpigmentation is the result of excessive melanin 
production by the pigment cells—melanocytes located 
in the basal layer of the epidermis. Existing treatment 
approaches use topically applied chemicals which activ-
ity either enhances the epidermal cell turn-over due to 
the peeling or exerts inhibitory action on the melanin 
synthesis machinery. The latter requires the penetration 
of skin barrier presented by stratum corneum and fur-
ther diffusion of the active substance through other epi-
dermal layers to target melanocytes in the basal layer. An 
efficient transdermal delivery system would increase the 
treatment efficacy and reduce the potential cytotoxicity 
of the active ingredient [5].
The aim of the present study is to evaluate the relative 
safety and inhibitory effect of four chemical compounds used 
in skin care and hyperpigmentation treatment products, and 
to further evaluate possible effects of micellar encapsulation 
on the most effective and least toxic candidate.
We compared the in  vitro capacity of arbutin, glycolic 
acid, hyaluronic acid and allantoin to inhibit melanin syn-
thesis while accessing their cytotoxicity (Fig. 1). It turns out 
that arbutin was most effective in suppressing the cellular 
melanin production while having the lowest cytotoxicity.
Previously, the micellar formulation has been used for 
transdermal delivery of glucosamine to treat osteoarthri-
tis, and improved Ritchie Articular Index pain score from 
the baseline (day 0) in all demographic group and further 
enhanced functional abilities were evidenced [23]. Our 
preliminary data indicate that the glucosamine concen-
tration in the mouse blood 2  h after the application of 
micellar glucosamine cream was about 10 times higher 
than that observed for oral delivery (Additional file  1: 
Figure S7). Here, arbutin was formulated with this tech-
nology and the activity of arbutin was retained in the for-
mulation, about 80 % as effective as free arbutin (Fig. 2).
Finally, the ex  vivo skin penetration experiment dem-
onstrated that the micellar arbutin cream possesses 
enhanced transdermal functionality (Fig.  3). During 
the first 4 h of the experiment the levels of arbutin pen-
etrated through the skin were similar for the micellar 
arbutin cream and non-micellar arbutin cream. However, 
the level rose dramatically thereafter for micellar arbutin 
compared to the non-micellar arbutin cream.
Fig. 3 Ex vivo skin penetration experiment: a illustration and a photo of Franz cell experiment. b Quantification of arbutin in the receiving well dur-
ing an 24-h incubation. *P < 0.05, **P < 0.01, as determined by one-way ANOVA
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Taken together our data provide evidence that micel-
lar arbutin formulation could improve arbutin delivery 
and thus enhance the suppression of melanin synthesis. 
Micellar arbutin therefore has the potential to be devel-
oped into transdermal delivery system to address hyper-
pigmentation skin disorders.
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